Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
16 Mai 2023 - 10:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2023
Commission File Number: 001-36582
Altamira Therapeutics Ltd.
(Translation of registrant’s name into English)
Clarendon House, 2 Church Street
Hamilton HM 11, Bermuda
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒
Form 40-F ☐
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Altamira Therapeutics Ltd. |
|
|
|
By: |
/s/ Thomas Meyer |
|
|
Name: |
Thomas Meyer |
|
|
Title: |
Chief Executive Officer |
|
Date: May 16, 2023
2
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Auris Medical Holding AG (NASDAQ): 0 Nachrichtenartikel
Weitere Altamira Therapeutics Ltd. News-Artikel